ArticleDigestive diseases (Basel, Switzerland)2026
Serum Anti-<italic>Saccharomyces cerevisiae</italic> Antibody Is Associated with Disease Severity in Patients with Primary Sclerosing Cholangitis.
Article in Digestive diseases (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: Primary sclerosing cholangitis (PSC) is a chronic liver disease accompanying inflammatory bowel disease (IBD). Anti-Saccharomyces cerevisiae antibody (ASCA) is a serological marker associated with aggressive IBD phenotype. Data on the association between ASCA and liver outcomes remain elusive. We aimed to explore whether ASCA seropositivity is associated with liver disease severity in people living with PSC-IBD.
methodsWe conducted a retrospective study on adult patients with PSC-IBD at a tertiary center, between 2010 and 2023. Medical records were reviewed for demographics, clinical, and laboratory data. Severity of liver disease was assessed using the Amsterdam-Oxford prognostic model (AOM) and liver stiffness measurement (LSM), assessed by vibration-controlled transient elastography (FibroScan®).
resultsThe cohort comprised of 58 subjects with PSC-IBD and an available ASCA result. Thirty patients were diagnosed with ulcerative colitis (UC) and 28 with Crohn's disease (CD). Six of 30 (20%) patients with UC and 14 of 28 patients (50%) with CD had positive ASCA. In a univariate analysis, AOM (p = 0.021) and LSM (p = 0.018) were significantly higher in those positive for ASCA. In a multivariable model, ASCA positivity remained significantly associated with higher AOM score (p = 0.026) and a higher LSM (p = 0.036), even after adjustment for IBD subtype and disease duration.
conclusionIn subjects with IBD with concomitant PSC, the presence of serum ASCA is associated with increased liver stiffness and AOM score, well-known markers for disease severity and reduced transplant-free survival. Further studies are warranted to validate these findings and to explore the biological mechanism underlying this association. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.